NQO2 and Alzheimer disease: Since genetic deletion of QR2 provides a proteomic profile antagonistic to AD and causes a reduction in metabolic stress, and since QR2 has been previously linked with AD and cognitive functions (6, 16, 17, 29, 30), it follows that QR2 inhibition is an attractive and, to our knowledge, novel candidate for neurodegenerative disease treatment in general and for AD drug development specifically.